-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec content team editor A few days ago, Autolus Therapeutics announced that its in-research CAR-T therapy obecabtagene autoleucel (obe-cel, also known as AUTO1) is in the treatment of a patient with indolent B-cell non-Hodgkin’s lymphoma (iNHL) A complete remission rate of 100% was achieved in the cohort, and no high-grade cytokine release syndrome and immune effector cell-related neurotoxicity syndrome (ICANS) were found in the patients
.
At the same time, in clinical trials for the treatment of patients with acute lymphoblastic leukemia (ALL), 85% of patients achieved minimal residual disease (MRD) negative complete remission after 1 month of treatment, and after 12 months and 24 months of treatment The posterior event-free survival rate (EFS) was 50.
2%, showing the durability of complete remission
.
Obe-cel is a CAR-T therapy targeting CD19 developed by Autolus
.
Its uniqueness is that the designed chimeric antigen receptor has a fast off-rate after binding to CD19.
This design can reduce the over-activation of T cells, thereby reducing toxic and side effects at the same time, Decreasing the rate of cell failure may improve the durability of CAR-T therapy
.
In clinical trials for the treatment of iNHL, 9 patients who were able to be evaluated all achieved complete metabolic remission at the third month of treatment, and 8 patients were still disease-free at a median follow-up time of 6.
1 months
.
No patient had any grade of ICANS and CRS above grade 3
.
▲Obe-cel's performance in a cohort of patients with indolent non-Hodgkin's lymphoma (picture source: reference [2]) In clinical trials for the treatment of ALL patients, the event-free survival rate (EFS) of the patients was 24 It was 50.
2% at month time, and this value has been stable after 12 months of treatment
.
▲Obe-cel's performance in the treatment of ALL patients (picture source: reference [2]) "The event-free survival rate of ALL patients remained stable during the 12-month and 24-month follow-up.
It supports obe-cel as a monotherapy and has a cure The potential of certain ALL patients
.
" Autolus CEO Dr.
Christian Itin said, "The early results obtained in patients with indolent B-cell non-Hodgkin lymphoma showed high levels of clinical activity and controllable safety characteristics
.
This means that obe-cel is expected to benefit a wider range of B-cell blood cancer patients
.
"Reference: [1] Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress.
Retrieved June 13, 2021, from https://autolus.
gcs-web.
com/news-releases/news-release-details/autolus-therapeutics-presents-new-data-obe-cel-rr-indolent-b[2] Obe-cel Data Update-EHA 2021.
Retrieved June 13, 2021, from https://autolus.
gcs-web.
com/static-files/b4ca8abe-8b75-4690-a9fd-2680e161f0f5 Note: This article aims to introduce the progress of medical and health research, not Recommended treatment plan
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
.
At the same time, in clinical trials for the treatment of patients with acute lymphoblastic leukemia (ALL), 85% of patients achieved minimal residual disease (MRD) negative complete remission after 1 month of treatment, and after 12 months and 24 months of treatment The posterior event-free survival rate (EFS) was 50.
2%, showing the durability of complete remission
.
Obe-cel is a CAR-T therapy targeting CD19 developed by Autolus
.
Its uniqueness is that the designed chimeric antigen receptor has a fast off-rate after binding to CD19.
This design can reduce the over-activation of T cells, thereby reducing toxic and side effects at the same time, Decreasing the rate of cell failure may improve the durability of CAR-T therapy
.
In clinical trials for the treatment of iNHL, 9 patients who were able to be evaluated all achieved complete metabolic remission at the third month of treatment, and 8 patients were still disease-free at a median follow-up time of 6.
1 months
.
No patient had any grade of ICANS and CRS above grade 3
.
▲Obe-cel's performance in a cohort of patients with indolent non-Hodgkin's lymphoma (picture source: reference [2]) In clinical trials for the treatment of ALL patients, the event-free survival rate (EFS) of the patients was 24 It was 50.
2% at month time, and this value has been stable after 12 months of treatment
.
▲Obe-cel's performance in the treatment of ALL patients (picture source: reference [2]) "The event-free survival rate of ALL patients remained stable during the 12-month and 24-month follow-up.
It supports obe-cel as a monotherapy and has a cure The potential of certain ALL patients
.
" Autolus CEO Dr.
Christian Itin said, "The early results obtained in patients with indolent B-cell non-Hodgkin lymphoma showed high levels of clinical activity and controllable safety characteristics
.
This means that obe-cel is expected to benefit a wider range of B-cell blood cancer patients
.
"Reference: [1] Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress.
Retrieved June 13, 2021, from https://autolus.
gcs-web.
com/news-releases/news-release-details/autolus-therapeutics-presents-new-data-obe-cel-rr-indolent-b[2] Obe-cel Data Update-EHA 2021.
Retrieved June 13, 2021, from https://autolus.
gcs-web.
com/static-files/b4ca8abe-8b75-4690-a9fd-2680e161f0f5 Note: This article aims to introduce the progress of medical and health research, not Recommended treatment plan
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
